Y-mAbs' Anticipated 2024 Total Net Revenues Now Expected To Be Between $87M-$95M Versus Consensus $95.18M
Portfolio Pulse from Benzinga Newsdesk
Y-mAbs Therapeutics has revised its anticipated 2024 total net revenues to be between $87M and $95M, slightly below the consensus estimate of $95.18M. The company expects operating expenses to remain between $115M and $120M, with total annual cash burn projected to stay between $15M and $20M.
August 12, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Y-mAbs Therapeutics has revised its 2024 revenue forecast to $87M-$95M, which is slightly below the consensus estimate of $95.18M. Operating expenses and cash burn projections remain unchanged.
The revision of the revenue forecast to a range slightly below the consensus estimate may lead to a negative short-term impact on the stock price as it indicates potential underperformance. However, the unchanged operating expenses and cash burn projections provide some stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100